Global Asthma & COPD Market Growth 2023-2029

Global Asthma & COPD Market Growth 2023-2029

Chronic obstructive pulmonary disease (COPD) is a general term that describes progressive respiratory diseases like emphysema and chronic bronchitis. COPD is characterized by decreased airflow over time, as well as inflammation of the tissues that line the airway.

Asthma is usually considered a separate respiratory disease, but sometimes it’s mistaken for COPD. The two have similar symptoms. These symptoms include chronic coughing, wheezing, and shortness of breath.

LPI (LP Information)' newest research report, the “Asthma & COPD Industry Forecast” looks at past sales and reviews total world Asthma & COPD sales in 2022, providing a comprehensive analysis by region and market sector of projected Asthma & COPD sales for 2023 through 2029. With Asthma & COPD sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Asthma & COPD industry.

This Insight Report provides a comprehensive analysis of the global Asthma & COPD landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Asthma & COPD portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Asthma & COPD market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Asthma & COPD and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Asthma & COPD.

The global Asthma & COPD market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

Currently, North America leads the global market for asthma & COPD drugs and devices. North America was followed by Europe in terms of market capitalization. However, North America and Europe is expected to lose out some of the market share to other emerging regional markets owing to the expiry of several patens of pharmaceutical companies operating in these regions. Asia Pacific is expected to be the fastest regional market for asthma and COPD owing to the increased incidence of asthma & other respiratory diseases in industrial regions.

This report presents a comprehensive overview, market shares, and growth opportunities of Asthma & COPD market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Anti-inflammatory Drugs
Bronchodilator Monotherapy
Combination Drugs

Segmentation by application
Hospital Pharmacies
Private Clinics
Drug Stores
Retail Pharmacies
E-Commerce

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Novartis
Merck
Abbott
Boehringer Ingelheim
AstraZeneca
Roche
Teva
Vectura
Pfizer
Mylan
Allergan
Cipla
Akorn

Key Questions Addressed in this Report

What is the 10-year outlook for the global Asthma & COPD market?

What factors are driving Asthma & COPD market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Asthma & COPD market opportunities vary by end market size?

How does Asthma & COPD break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.